Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIOH-1
2023-510088-37-00Phase 3Completed
- Sponsor
- AiCuris
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of pritelivir in aciclovir-resistant herpes simplex virus infection and herpes simplex (HSV) (4 arms), sponsored by AiCuris. Primary endpoint: Cure rate during treatment period up to 28 days. Started Mar 2022; status: completed.
02
Drugs
pritelivir
03
Conditions
aciclovir-resistant herpes simplex virus infectionherpes simplex (HSV)
Beyond the preview
Go deeper on 2023-510088-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510088-37-00.